Victorians are taking peptides for everything from weight loss and body building to skin improvements. Many end up in hospitals with severe side effects.
Pharmaceutical giant Eli Lilly on Friday declined a recommendation to have the government subsidise its Mounjaro drug for Australians with Type 2 diabetes.
A ubiquitous molecule could help treat obesity and heart disease,rewriting half a century of knowledge.
Generic versions of the drug can cost as little as $20 a month overseas,in a glimpse of the future for Australia.
Australian tech health providers say they are keen to offer an oral pill version of the class of medications,which previously required injections.
Former body positivity influencers are fleeing the movement,while “skinny culture” is making an alarming comeback.
Analysts say Novo Nordisk’s new obesity drug may be obsolete before it hits the shelves,underlining a massive fall from grace for the company behind the weight loss boom.
A new major review of research found no evidence to support the method as any better for weight loss than other diets.
Such “conditions” are not medical issues. They’re a way for cosmetic surgeons to sell you something.
Inappropriate prescribing and poor support are triggering anorexia in previously healthy patients taking weight-loss medications.